E2F4 activity level significantly correlates with survival time in bladder cancer (P = 0.01) and glioblastoma (P = 0.007), but not in NSCLC, AML or Burkitt’s lymphoma (P >0.05). Here, E2F4 is linked to urinary bladder cancer.